- Third Quarter 2022 Financial Results
- Revenue of $1,028 million
- Reported Net Loss of $49 million, Adjusted Net Income of $96 million
- Adjusted EBITDA of $205 million or 19.9% of Revenue
- Reported EPS of $(0.10), Adjusted EPS of $0.20
- Net leverage ratio decreased to 5.2x Adjusted EBITDA
- Updating full year 2022 guidance to reflect current assumptions:
- Revenue of $4,385 to $4,430 million
- Reported Net Loss of $(82) to $(57) million, Reported diluted EPS of $(0.17) to $(0.12)
- Adjusted EPS of $1.01 to $1.07, Adjusted EBITDA of $1,010 to $1,045 million
- Net leverage ratio expected at 5.2x to 5.3x Adjusted EBITDA at year-end 2022
- Initiated submission for broad spectrum parasiticide to the U.S. FDA with approval expected in 12 to 18 months; expect approval of first SGLT-2 product for feline diabetes and conditional approval of first monoclonal antibody treatment for parvovirus by late 2022 or early 2023.
GREENFIELD, IN (November 8, 2022) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2022, provided guidance for the fourth quarter of 2022, and updated guidance for the full year 2022.
